Abstract
Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD). Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM-IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis-mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker. Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion-chromatography-fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non-MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut-off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non-MDD subjects, AUC was 0.89, with sensitivity/specificity of 86% and 100%, respectively, at a cut-off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation. Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 349-361 |
| Number of pages | 13 |
| Journal | Psychiatry and Clinical Neurosciences |
| Volume | 72 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2018 |
| Externally published | Yes |
Fingerprint
Keywords
- biomarker
- diagnosis
- major depressive disorder
- metabolomics
- phosphoethanolamine
ASJC Scopus subject areas
- Neuroscience(all)
- Neurology
- Clinical Neurology
- Psychiatry and Mental health
Cite this
Plasma metabolome analysis of patients with major depressive disorder. / Kawamura, Noriyuki; Shinoda, Kosaku; Sato, Hajime; Sasaki, Kazunori; Suzuki, Makoto; Yamaki, Kumi; Fujimori, Tamaki; Yamamoto, Hiroyuki; Osei-Hyiaman, Douglas; Ohashi, Yoshiaki.
In: Psychiatry and Clinical Neurosciences, Vol. 72, No. 5, 01.05.2018, p. 349-361.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Plasma metabolome analysis of patients with major depressive disorder
AU - Kawamura, Noriyuki
AU - Shinoda, Kosaku
AU - Sato, Hajime
AU - Sasaki, Kazunori
AU - Suzuki, Makoto
AU - Yamaki, Kumi
AU - Fujimori, Tamaki
AU - Yamamoto, Hiroyuki
AU - Osei-Hyiaman, Douglas
AU - Ohashi, Yoshiaki
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD). Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM-IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis-mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker. Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion-chromatography-fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non-MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut-off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non-MDD subjects, AUC was 0.89, with sensitivity/specificity of 86% and 100%, respectively, at a cut-off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation. Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.
AB - Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD). Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM-IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis-mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker. Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion-chromatography-fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non-MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut-off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non-MDD subjects, AUC was 0.89, with sensitivity/specificity of 86% and 100%, respectively, at a cut-off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation. Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.
KW - biomarker
KW - diagnosis
KW - major depressive disorder
KW - metabolomics
KW - phosphoethanolamine
UR - http://www.scopus.com/inward/record.url?scp=85043267038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043267038&partnerID=8YFLogxK
U2 - 10.1111/pcn.12638
DO - 10.1111/pcn.12638
M3 - Article
C2 - 29356314
AN - SCOPUS:85043267038
VL - 72
SP - 349
EP - 361
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
SN - 1323-1316
IS - 5
ER -